

Can vitamin D improve symptoms and quality of life in people with irritable bowel syndrome (IBS)?

Submission date 23/03/2018	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 25/04/2018	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 02/08/2021	Condition category Digestive System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Irritable bowel syndrome (IBS) is a common condition that affects the digestive system. IBS is usually experienced for a life-time and symptoms include bloating, constipation, diarrhoea, and stomach cramps. These symptoms can affect a person for days, weeks or even months at a time. This can be a difficult condition to live with and can have a large impact on a person's everyday life. The cause of IBS is unknown, although it is thought to be associated with a family history of IBS, stress and certain foods. IBS cannot be cured but can often be managed with medication and dietary changes. Research has shown that people with IBS also have low levels of vitamin D. The aim of this study is to assess whether increasing vitamin D levels in people with IBS helps to improve their symptoms.

Who can participate?

Men and women aged between 18-60 years with a diagnosis of IBS

What does the study involve?

Each person will be put into one of two groups to receive either a vitamin D or placebo (dummy) supplement mouth spray to be taken each day for 12 weeks. All participants will be asked to fill in a total of seven Symptom Severity Questionnaires (SSS-IBS), two Quality of Life Questionnaires (QoL), and one Food Frequency Questionnaire (FFQ). All participants will have blood samples taken at the first and last appointment. This will be done with a finger prick blood test kit. All participants will take a mouth spray, only half of the volunteers will get the active (real) vitamin D supplement.

What are the possible benefits and risks of participating?

The supplement that participants will be taking are well under the advised limit, however, there is a very unlikely risk of vitamin D levels going too high. Side effects of excessive vitamin D levels include raised calcium blood levels, nausea and constipation. Participants will be monitored closely for any problems they may experience during the study. There will also be small risks involved with taking blood samples, such as pain around the site of insertion, as with any blood test. These risks will be clearly explained to the participants. The

finger prick only occurs twice; at the start and end of the 12 weeks. Volunteers on the active (real) supplement may benefit from their participation in the research as they may see an improvement in their symptoms and all volunteers will receive a £50.00 voucher as a thank you for their participation.

Where is the study run from?

This study will be run from the Medical School at the University of Sheffield.

When is the study starting and how long is it expected to run for?

Recruitment will occur three times over the next 2 years. The first two rounds will occur in the winter periods (Jan-Apr) in 2018 and 2019 in the local area with the goal of reaching 160 volunteers. A further recruitment will take place in 2019 to recruit volunteers from outside the local area and will use postal and online methods to complete the research. The anticipated start date of the trial is September 2018 and will run until September 2020.

Who is funding the study?

This research has been part funded by the University of Sheffield and by an industry partner BetterYou.

Who is the main contact?

The main person to contact regarding this study is Dr Bernard Corfe, Senior Lecturer in Oncology Principal Investigator in Molecular Gastroenterology, Fellow of Insigneo, b.m.corfe@sheffield.ac.uk.

Contact information

Type(s)

Scientific

Contact name

Dr Bernard Corfe

Contact details

The University of Sheffield
The Medical School
Beech Hill Road
Sheffield
S10 2RX
United Kingdom
Sheffield
United Kingdom
S10 2RX

Type(s)

Public

Contact name

Mrs Claire Williams

Contact details

The Medical School
Beech Hill Road
Sheffield
S10 2RX
United Kingdom
Sheffield
United Kingdom
S10 2RX
07925034693
cewilliams1@sheffield.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

016753

Study information

Scientific Title

To assess whether an increase of vitamin D in subjects with irritable bowel syndrome improves symptoms (D-IBS)

Acronym

D-IBS

Study objectives

The hypothesis is that a 3000 IU vitamin D supplement will reduce symptom severity and improve quality of life compared with placebo in participants with IBS, based on self-reported outcomes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

University of Sheffield, 19/12/2017, Registration number: 160216727, Reference Number: 016753

Study design

Double-blind placebo-controlled two-arm parallel-design study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Home

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Irritable bowel syndrome

Interventions

Patients administered 3000 IU (75 microg) vitamin D sublingual spray or placebo sublingual spray once daily for 12 weeks

Intervention Type

Supplement

Primary outcome measure

Reduction in Total Symptom Severity for IBS, measured by visual analogue scale (VAS) at baseline and exit, and a cumulative measure taken fortnightly across the intervention period (weeks 0, 2, 4, 6, 8, 10, 12).

Secondary outcome measures

1. Serum vitamin D concentrations will be assessed at baseline and exit: bloodspots will be taken and analysed by liquid chromatography-mass spectrometry .
2. Quality of life is assessed at baseline and exit using The Irritable Bowel Syndrome - Quality of Life questionnaire (IBS-QOL)

Overall study start date

01/09/2017

Completion date

30/09/2020

Eligibility

Key inclusion criteria

Clinical diagnosis of IBS using the ROME criteria and reaching severity score of 150 on SSS scale at time of recruitment. As some participants may have active IBS but historic diagnosis, no one version of ROME is specified as long as a clinical diagnosis was made at the time.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

160

Total final enrolment

135

Key exclusion criteria

1. Pregnant or lactating
2. Regular use of nutritional supplements
3. BMI >30 kg/m²
4. BMI <18 kg/m²
5. Any history of gastrointestinal disorders (Crohn's disease, ulcerative colitis, diverticulitis)
6. Diabetes mellitus

Date of first enrolment

08/01/2018

Date of final enrolment

30/07/2020

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

The University of Sheffield

The Medical School

Beech Hill Road

Sheffield

S10 2RX

United Kingdom

Sheffield

United Kingdom

S10 2RX

Sponsor information

Organisation

The University of Sheffield

Sponsor details

The Medical School
Beech Hill Road
Oncology and Metabolism
Sheffield
England
United Kingdom
S10 2RX

Sponsor type

University/education

ROR

<https://ror.org/05krs5044>

Funder(s)**Funder type**

Not defined

Funder Name

BetterYou

Funder Name

The University of Sheffield

Results and Publications**Publication and dissemination plan**

Planned publication in a high-impact peer reviewed journal

Intention to publish date

30/09/2020

Individual participant data (IPD) sharing plan

As there are no repositories for trial data, we will share an annotated, anonymised spreadsheet on request following publication of any papers.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type

[Results article](#)

Details

Date created

30/07/2021

Date added

02/08/2021

Peer reviewed?

Yes

Patient-facing?

No